HIC
AZN icon

Hamrick Investment Counsel’s AstraZeneca AZN Stock Holding History

Hamrick Investment Counsel’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2
Closed -$276 – 360
2025
Q4 		$276 Buy
+2
New +$351 ﹤0.01% 182

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Hamrick Investment Counsel's AZN Position: Q1 2026 in Review

Hamrick Investment Counsel sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 2 shares — an estimated $276 sold.

Hamrick Investment Counsel first reported a position in AZN in Q4 2025 and held it in 1 quarter. The position peaked at $276 in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Hamrick Investment Counsel reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Hamrick Investment Counsel sold 2 AstraZeneca shares in Q1 2026, an estimated $276.
  • Hamrick Investment Counsel first reported a position in AstraZeneca in Q4 2025 and held it in 1 quarter.
  • Hamrick Investment Counsel's AstraZeneca position peaked at $276 in Q4 2025.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Hamrick Investment Counsel's 13F filing for Q1 2026, filed 11 May 2026.